FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company's common stock with an exercise price of $10.18, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on July 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on July 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
Cartesian Therapeutics, Inc.(RNAC)Earnings, Financials & Key Ratios
RNAC•NASDAQ
$10.05
Price updated Jul 7, 2026
AboutSelecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$3M-92.8%
- EBITDA-$87M-102.8%
- Net Income-$130M-68.3%
- EPS (Diluted)-5.02-52.6%
- Gross Margin100%
- EBITDA Margin-3099.93%-2722.0%
- Operating Margin-3099.93%-2648.0%
- Net Margin-4658.63%-2241.4%
RNAC Price & Volume
Cartesian Therapeutics, Inc. (RNAC) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pivot Strains Liquidity and Equity Base
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
Key Thesis Takeaways
- Cartesian Therapeutics faces a precarious financial outlook as it transitions to a pre-commercial mRNA-engineered cell therapy model, characterized by a 92.81% year-over-year revenue collapse in 2026Q1.
- The company's reliance on external capital to fund persistent R&D expenditures has resulted in a significant equity deficit of $148.1 million, raising concerns regarding long-term solvency.
- Investors should monitor the clinical validation of the firm's pipeline, as the current cash burn rate and lack of recurring revenue streams may necessitate further dilutive financing to sustain operations.
Verdict Logic
the company's cash reserves have declined to $118.6 million as of 2026Q1, and the absence of recurring revenue suggests significant ongoing execution and dilution risks.
RNAC Growth Metrics
Cartesian Therapeutics, Inc. (RNAC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.37%
5 Years-29.96%
3 Years-70.66%
TTM-94.81%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-296.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-325.69%
Return on Capital
10 Years-56.54%
5 Years-15.39%
3 Years-28.1%
Last Year-25%
RNAC Recent Earnings
Cartesian Therapeutics, Inc. (RNAC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$1.46-73.8%
$0.84
Rev
$78,000-64.5%
$219,800
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$1.38-68.3%
$0.82
Rev
$947,000+529.9%
$150,333
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.38-70.4%
$0.81
Rev
$452,000+351.0%
$100,220
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.50+165.8%
$0.76
Rev
$298,000+67.8%
$177,560
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.46vs $0.84-73.8% | $78,000vs $219,800-64.5% |
| Q2 2026 | Mar 9, 2026 | $1.38vs $0.82-68.3% | $947,000vs $150,333+529.9% |
| Q4 2025 | Nov 6, 2025 | $1.38vs $0.81-70.4% | $452,000vs $100,220+351.0% |
| Q3 2025 | Aug 7, 2025 | $0.50vs $0.76+165.8% | $298,000vs $177,560+67.8% |
Based on last 12 quarters of dataView full earnings history →
Latest RNAC News
Recent stock market news and headlines for Cartesian Therapeutics, Inc. (RNAC)
GlobeNewsWire·5 days ago
Cartesian Therapeutics Announces New Employment Inducement GrantsZacks Investment Research·6 days ago
New Strong Sell Stocks for July 1stCZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
Peers Comparison
Key metrics vs top competitors for Cartesian Therapeutics, Inc. (RNAC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.05 | $295.28M | -2.00 | -92.81% | -4658.63% | — | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — |
Compare RNAC vs Peers
Cartesian Therapeutics, Inc. (RNAC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RNAC SEC Filings & Documents
Cartesian Therapeutics, Inc. (RNAC) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 9, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when RNAC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RNAC Frequently Asked Questions
Cartesian Therapeutics, Inc. (RNAC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Cartesian Therapeutics, Inc.'s revenue?
Cartesian Therapeutics, Inc. (RNAC) reported $1.8M in revenue for fiscal year 2025. This represents a 42% decrease from $3.0M in 2014.
How fast is Cartesian Therapeutics, Inc. growing?
Cartesian Therapeutics, Inc. (RNAC) saw revenue decline by 92.8% over the past year.
Is RNAC profitable?
Cartesian Therapeutics, Inc. (RNAC) reported a net loss of $151.8M for fiscal year 2025.
Dividend & Returns
What is Cartesian Therapeutics, Inc.'s free cash flow?
Cartesian Therapeutics, Inc. (RNAC) had negative free cash flow of $77.4M in fiscal year 2025, likely due to heavy capital investments.